A data-focused analysis of Q4 2025 institutional portfolio filings. Numbers sourced from SEC 13F disclosures via 13F Insight.
When one of the world's most sophisticated quantitative hedge funds reshuffles its entire portfolio in a single quarter, the market pays attention. Two Sigma Investments, the $70.9 billion systematic powerhouse, did exactly that in Q4 2025 — executing a remarkably symmetrical portfolio overhaul with 168 new positions and 168 exits.
The message from Two Sigma's algorithms is unmistakable: get out of financials, get into technology, biotech, and real estate. The fund dumped its entire $583 million XLF financial sector ETF position while simultaneously building massive stakes in XLK (Technology Select Sector SPDR, $403M) and VNQ (Vanguard Real Estate ETF, $316M).
The Numbers Behind the Rotation
Two Sigma's Q4 2025 13F filing reveals a fund that grew its assets under management from $67.2 billion to $70.9 billion while fundamentally restructuring its sector exposure. The fund now holds 4,041 positions, up from 3,628 last quarter — but the composition has shifted dramatically.
[Interactive chart available in original article]
The top 10 holdings paint a picture of a fund that favors broad market exposure through ETFs and options overlays. The largest position is a $481 million basket tracked as US Tech Breakthrough, followed by a $444 million Berkshire Hathaway put position. Growth-oriented ETFs dominate: XLY ($404M), XLK ($403M), VUG ($399M), and IWF ($385M) collectively represent over $1.5 billion in growth-tilted exposure.
Sector Exodus: Financials Out, Tech and Biotech In
The most striking move was the complete liquidation of XLF, which had been a $583 million position — Two Sigma's third-largest holding last quarter. Alongside XLF, the fund also exited individual financial names including Bank of America ($256M) and reduced its consumer staples exposure by selling 92% of its XLP position.
What replaced those financials? A decisive pivot to technology and biotech:
XLK (Technology Select Sector SPDR): New $403M position — a pure-play bet on the tech sector
VNQ (Vanguard Real Estate ETF): New $316M position — a rate-sensitive play
IBB (iShares Biotechnology ETF): New $249M position — healthcare innovation exposure
XLY (Consumer Discretionary): Surged 860% to $404M
[Interactive chart available in original article]
Reading the Quant Signals
Two Sigma isn't a discretionary fund making gut calls — it's a machine learning-driven operation founded by mathematician David Siegel and computer scientist John Overdeck. When its models produce a 168-in/168-out turnover in a single quarter, it signals a fundamental shift in the quantitative factors driving returns.
The rotation from financials to technology suggests Two Sigma's models identified several converging signals:
Rate cycle positioning: Exiting XLF while adding VNQ (real estate) suggests the models expect a rate environment less favorable to bank net interest margins but more supportive of real estate valuations
Growth factor re-engagement: The massive buildup in growth ETFs (XLY +860%, NFLX +680%, ARM +568%) indicates the models see renewed momentum in growth factors
Biotech catalyst window: The new $249M IBB position may reflect model signals around FDA approval cycles and biotech M&A activity
The Options Overlay Strategy
Notably, many of Two Sigma's largest positions carry put options overlays. Berkshire Hathaway ($444M), Rivian ($378M), SPY ($377M), Apple ($376M), NVIDIA ($363M), and Palantir ($352M) are all held with put protection. This suggests the fund is bullish on growth exposure but hedging against downside risk — a classic quant approach to maintaining asymmetric return profiles.
Growth Trajectory
Two Sigma's AUM has grown 55% year-over-year, from $45.9 billion in Q4 2024 to $70.9 billion in Q4 2025. Over five years, the fund has surged 251% from $20.2 billion. The accelerating growth — $56.5B in Q2 2025 to $67.2B in Q3 to $70.9B in Q4 — reflects both market appreciation and net inflows into the firm's systematic strategies.
What It Means for Investors
Two Sigma's sector rotation carries particular weight because of its systematic nature. Unlike a portfolio manager's opinion, these moves reflect algorithmic signals processed across vast datasets. The fund's complete exit from financials and aggressive entry into tech, biotech, and real estate ETFs suggests its models see a macro environment where:
Technology leadership will persist and potentially broaden
Financial sector tailwinds from higher rates are fading
Biotech and real estate offer asymmetric upside
Growth factors are re-asserting dominance over value
For retail investors tracking institutional "smart money," Two Sigma's moves are worth monitoring closely. The symmetry of the rotation — exactly 168 positions in, 168 positions out — suggests a deliberate, model-driven rebalancing rather than ad hoc trading. When algorithms with a 20+ year track record speak this clearly, it pays to listen.
View the full Two Sigma portfolio and filing history on 13F Insight.
Working With 13F Filing Data
Key context for interpreting these numbers:
- Filing lag: 45-day delay means Q4 2025 data was filed by Feb 14, 2026
- AUM threshold: Only funds managing ≥$100M in US equities must file
- Long-only scope: Shorts, derivatives, bonds, and foreign securities are excluded
- Snapshot nature: The 13F reflects end-of-quarter positions, not intra-quarter activity
For historical trend analysis, multi-quarter comparisons, and full position-level data across 5,000+ institutional filers, visit 13F Insight.
Originally published at 13finsight.com
Top comments (0)